This paper is in the following e-collection/theme issue:

Breast Cancer (200) Mobile Health (mhealth) (2748) Patient-Reported Outcome Measures (PROMs) (275) mHealth for Symptom and Disease Monitoring, Chronic Disease Management (1302) Innovations and Technology in Cancer Care (400) Cancer Self-Management (44)

Published on in Vol 10 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/54178, first published .
Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes

Authors of this article:

Andreas Trojan1, 2 Author Orcid Image ;   Sven Roth3 Author Orcid Image ;   Ziad Atassi2 Author Orcid Image ;   Michael Kiessling2 Author Orcid Image ;   Reinhard Zenhaeusern4 Author Orcid Image ;   Yannick Kadvany5 Author Orcid Image ;   Johannes Schumacher6 Author Orcid Image ;   Gerd A Kullak-Ublick1 Author Orcid Image ;   Matti Aapro7 Author Orcid Image ;   Alexandru Eniu8 Author Orcid Image
Article Authors Cited by Tweetations (2) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.